Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 8/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.58 |
| ▸ | HTR3B | O95264 | 2/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 6/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22422339 | 0.87 | ADRB1 (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL14924034 | 0.83 | ADRB1 (0.51) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL20883739 | 0.83 | ADRB1 (0.46) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL17660600 | 0.83 | CDK1 (0.43) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL13450375 | 0.83 | ALDH1A1 (0.54) | — | |
| SCHEMBL25678836 | 0.81 | HTR3E (0.39) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL12352558 | 0.81 | ALDH1A1 (0.46) | HTR3AHTR1AHTR6DRD2DRD3 | |
| SCHEMBL20883751 | 0.81 | HTR3A (0.41) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL20883659 | 0.81 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL25678607 | 0.80 | LMNA (0.45) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20160264570-A1 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | LOYOLA UNIVERSITY OF CHICAGO | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | HTR3A 4004/4885HTR3E 1399/4885HTR3B 3800/4885 |
| US-20160264570-A1 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | PLK1, TUBA1C, PPT1 | HTR3A 2492/4885HTR3E 3654/4885HTR3B 3023/4885 |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAK4, PAK2, PAK1 | HTR3A 4299/4885HTR3E 3649/4885HTR3B 3773/4885 |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | HTR3A 4004/4885HTR3E 1399/4885HTR3B 3800/4885 |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | HTR3A 4388/4885HTR3E 2896/4885HTR3B 4393/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | HTR3A 4372/4885HTR3E 2712/4885HTR3B 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.